Methyl (E)-4-[[(2S)-2-amino-3-(methylamino)-3-oxopropyl]amino]-4-oxobut-2-enoate;hydrochloride
C9H16ClN3O4 — CID 118726791
Data last refreshed: (MolForge compound catalog, from PubChem)
About Methyl (E)-4-[[(2S)-2-amino-3-(methylamino)-3-oxopropyl]amino]-4-oxobut-2-enoate;hydrochloride
Methyl (E)-4-[[(2S)-2-amino-3-(methylamino)-3-oxopropyl]amino]-4-oxobut-2-enoate;hydrochloride (PubChem CID 118726791) has the molecular formula C9H16ClN3O4 and a molecular weight of 265.70 g/mol. Its IUPAC name is methyl (E)-4-[[(2S)-2-amino-3-(methylamino)-3-oxopropyl]amino]-4-oxobut-2-enoate;hydrochloride.
Molecular Properties
| Compound Name | Methyl (E)-4-[[(2S)-2-amino-3-(methylamino)-3-oxopropyl]amino]-4-oxobut-2-enoate;hydrochloride |
|---|---|
| PubChem CID | 118726791 |
| Molecular Formula | C9H16ClN3O4 |
| Molecular Weight | 265.70 g/mol |
| Exact Mass | 265.08 |
| IUPAC Name | methyl (E)-4-[[(2S)-2-amino-3-(methylamino)-3-oxopropyl]amino]-4-oxobut-2-enoate;hydrochloride |
| SMILES | CNC(=O)[C@@H](N)CNC(=O)/C=C/C(=O)OC.Cl |
| InChI | InChI=1S/C9H15N3O4.ClH/c1-11-9(15)6(10)5-12-7(13)3-4-8(14)16-2;/h3-4,6H,5,10H2,1-2H3,(H,11,15)(H,12,13);1H/b4-3+;/t6-;/m0./s1 |
| InChIKey | LIYYAGWORYKUDA-GNPWLAFSSA-N |
| XLogP | -1.67 |
| TPSA | 110.52 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 17 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 265.70 |
| LogP ≤ 5 | -1.67 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 5 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118726791 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.